- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02243865
Chordate System Prophylactic Migraine Clinical Investigation
A Randomized, Placebo-controlled, Double-blind, Multi-center Clinical Investigation to Evaluate the Prophylactic Effect and Tolerability of Intranasal Kinetic Oscillation Stimulation (KOS) Using the Chordate System S200 in Migraine Patients
Study Overview
Status
Conditions
Detailed Description
This was a prospective, interventional, randomized, placebo-controlled, double-blind, multi-center clinical investigation of a medical device system.
A pilot study in which patients with frequent migraine attacks received intranasal KOS or placebo using the Chordate System S200 on two occasions.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Helsingborg, Sweden, 25220
- Stortorgets neurologmottagning
-
Linköping, Sweden, 582 19
- Läkarcentrum Stångåblick
-
Stockholm, Sweden, 11433
- Neurolgy Clinic
-
Vällingby, Sweden, 162 68
- Neurologmottagningen Vällingby sjukhus
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject is legally competent, has been informed of the nature, the scope and the relevance of the study, voluntarily agrees to participation and the study's provisions, and has duly signed the Informed Consent Form (ICF).
- Male or female aged between 18 and 65 years
- Diagnosed as suffering from migraine with or without aura according to International Headache Society´s (IHS) classification (International Classification of Headache Disorders (ICHD), 3rd edition, beta version)
- Reported history of 3 to 8 migraine episodes per month during previous 2 months, confirmed during baseline
- Reported history of at least 48 hours of freedom from headache between migraine attacks, confirmed during baseline
- Onset of migraine headache occurred before age 50
- Reported history of migraine for more than one year
- Reported stable dose of prophylactic migraine medication(s), if any, during the two months prior to screening (visit 1), and willing and able to maintain stable dose(s) until the three months follow-up (visit 4)
Exclusion Criteria:
- Meeting the ICHD criteria for medication overuse
- Reported history of 15 or more headache days per month (i.e. headaches of any kind), confirmed during baseline
- Reported frequency of non-migraine headaches exceeding 6 days per month, confirmed during baseline
- Unable to distinguish between migraine headaches and other headache types
- Treatment with Botox received within 6 months of the screening visit, or between the screening and treatment visits
- Ongoing treatment with implanted stimulator or other implanted device in the head and/or neck region
- Known pronounced anterior septal deviation, or other known relevant abnormality in the nasal cavity, including bacterial infection and wounds
- History of sinus surgery, transphenoidal surgery for pituitary or other lesions or cerebrospinal fluid (CSF) rhinorrhea
- Fitted with a pacemaker/defibrillator
- Previously treated with therapeutic radiation to the face (that could have influenced the nasal mucosa)
- Ongoing upper respiratory tract infection or a body temperature >38.5°C (at treatment), or malignancy in the nasal cavity
- History of regular nose bleeding (epistaxis), or concomitant condition that could cause excessive bleeding, including treatment with the anticoagulant Varan
- Head injury or open wound that contraindicates use of Chordate Headband
- Known allergy to polyvinylchloride, a material used in the Catheter, or medicinal liquid paraffin
- Concurrent condition or risk of non-compliance that, in the investigator's opinion, may affect the interpretation of performance or safety data or which otherwise contraindicates participation in a clinical investigation
- Any change in migraine prophylaxis the previous two months
- Pregnant women
- Participation in a clinical research study within three months of enrolment or planned participation at any time during this clinical investigation
- Employees of the study site or the sponsor directly involved with the conduct of the study, or immediate family members or any such individuals
- Headache or migraine episode within the 48 hours prior to the first treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Chordate S200 + control module (CT100), active
Chordate System S200 giving Kinetic Oscillation Stimulation Treatment for 15 minutes in each nostril
|
Chordate S200 + CT100 (active treatment) gives Kinetic Oscillation Stimulation for 15 minutes to each nostril and by that giving an effect on the autonomic nervous system (ANS).
|
Placebo Comparator: Chordate S200 + control module (CT100), placebo
Chordate System S200 giving Kinetic Oscillation Stimulation in placebo mode.
Non-inflated and non-vibrating treatment
|
Chordate S200 + CT100 (placebo) is used in the same way as Active treatment, but no Kinetic Oscillation Stimulation is given.
Catheter is not inflated and no vibration is given.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Number of Migraine Days Per Four Weeks During the Three Months Post Treatment Investigation Duration
Time Frame: From baseline (28 days pre-treatment) to visit 4 (day 98, ± 7 days)
|
A diary was used where patients added information each day on experienced migraine (yes/no). Baseline was defined as any migraine days from Day -29 until Day -1, i.e. the day before first treatment (Day 1). If full time period for baseline or the post treatment period was not documented, number of migraine days was recalculated with the formula: Number of migraine days = (Number of migraine days x 28) / Number of days observed If data was missing for any patient for more than 14 days during any period of interest, that patient was excluded from analysis. The change from baseline in number of migraine days was calculated as follows: Change = number of migraine days per four weeks for the 3 months post treatment period - number of migraine days per four weeks of the baseline period As the difference between the post treatment period and baseline is presented, negative numbers indicate a post treatment decrease in number of migraine days. |
From baseline (28 days pre-treatment) to visit 4 (day 98, ± 7 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Number of Migraine Days During the 1st, 2nd and 3rd Month and During the Final Four Weeks of the Three Month Post Treatment Investigation Duration
Time Frame: From baseline (28 days pre-treatment) to visit 4 (day 98, ± 7 days)
|
A diary was used where patients added information each day on experienced migraine (yes/no). Baseline was defined as any migraine days from Day -29 until Day -1, i.e. the day before first treatment (Day 1). If the full time period for either baseline or post treatment period was not documented number of migraine days was recalculated with the formula: Number of migraine days = (Number of migraine days x 28) / Number of days observed If data was missing for any patient for more than 14 days during any period of interest, that patient was excluded from the analysis of that time period. The change from baseline in number of migraine days was calculated as follows: Change = number of migraine days per four weeks for applicable post treatment period - number of migraine days per four weeks of the baseline period As the difference between applicable post treatment period and baseline is presented, negative numbers indicate a post treatment decrease in number of migraine days. |
From baseline (28 days pre-treatment) to visit 4 (day 98, ± 7 days)
|
Responder Rate
Time Frame: From baseline (28 days pre-treatment) to visit 4 (day 98, ± 7 days)
|
"Responder" defined as a patient with 50% or greater decrease in the number of migraine days per four weeks, for the 1st, 2nd and 3rd month post treatment vs baseline
|
From baseline (28 days pre-treatment) to visit 4 (day 98, ± 7 days)
|
Maximum Migraine Pain Intensity During the 1st, 2nd and 3rd Month, the Final 4 Weeks and the Complete Three Month Post Treatment Investigation Duration
Time Frame: From baseline (day ≥ - 28 days) to visit 4 (day 98, ± 7 days)
|
A diary was used where patients added information on the maximum pain intensity on each day according to a 4-point categorical scale (none, mild, medium, severe). The maximum documented pain intensity for each patient during each post treatment time period was tabulated for the active treatment and placebo groups. |
From baseline (day ≥ - 28 days) to visit 4 (day 98, ± 7 days)
|
Mean Change From Baseline in Median Migraine Duration (Hours/Day) During the 1st, 2nd and 3rd Month, the Final 4 Weeks and the Complete Three Month Post Treatment Investigation Duration
Time Frame: From baseline (28 days pre-treatment) to visit 4 (day 98, ± 7 days)
|
A diary was used where patients added information each day on the number of hours with migraine. The median migraine duration in hours per day was determined for each patient, for each post treatment time period. Baseline for each patient was defined as the median number of migraine hours/day from Day -29 until Day -1, i.e. the day before the first treatment (Day 1). The change in median migraine hours/day from baseline, for each defined post treatment time period, was then determined and the mean change is presented. As the differences between applicable post treatment period and baseline is presented, negative numbers indicate a post treatment decrease in number of migraine hours/day. |
From baseline (28 days pre-treatment) to visit 4 (day 98, ± 7 days)
|
Change From Baseline in Drug Consumption for Acute Treatment During the Three Month Post Treatment Investigation Duration
Time Frame: From baseline (28 days pre-treatment) to visit 4 (day 98, ± 7 days)
|
From baseline (28 days pre-treatment) to visit 4 (day 98, ± 7 days)
|
|
Patient's Satisfaction as Measured on Clinical Global Impression Scales (CGI)
Time Frame: At visit 4 day 98, ± 7 days
|
Patient satisfaction, evaluated by a clinician, was measured using 8-point clinical global impression (CGI) scores on an improvement scale (CGI-I: compared to condition at baseline, how much has changed: 0 = Not assessed, 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse).
|
At visit 4 day 98, ± 7 days
|
Number of Participants With a Change in Disease-specific Quality of Life From Baseline to End of the Three Month Investigation Duration
Time Frame: From baseline (day 0, visit 2) to visit 4 (day 98, ± 7 days)
|
Number of Participants with a Change in Disease-specific Quality of Life, as measured by EQ-5D-3L, from Baseline (day 0, visit 2 before first treatment) to End of the Three Month Investigation Duration.
EQ-5D-3L uses 5 categorical dimensions - motility, self-care, usual activities, pain/discomfort and anxiety/depression, each classified as improved, no change or worsened.
|
From baseline (day 0, visit 2) to visit 4 (day 98, ± 7 days)
|
Disease-specific Quality of Life (VAS Pain Scale) From Baseline to End of the Three Month Study Duration
Time Frame: From baseline (day 0, visit 2) to visit 4 (day 98, ± 7 days)
|
Disease-specific quality of life, as measured by EQ-VAS, at baseline (day 0, visit 2 before first treatment) and at end of the three month study duration after treatment.
The EQ VAS is a standard vertical 20 cm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a score from 0-100, where a higher score indicates greater pain intensity.
|
From baseline (day 0, visit 2) to visit 4 (day 98, ± 7 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Jan-Åke Åkesson, MD, Linkoeping University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PM005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on Chordate System S200 + CT100 (active treatment)
-
Chordate MedicalCompleted
-
Chordate MedicalTerminated
-
Chordate MedicalFGK Clinical Research GmbH; Vinnova (Swedish Governmental Agency for Innovation...CompletedChronic MigraineFinland, Germany
-
Halmstad County HospitalCompletedNon-allergic Rhinitis.Sweden
-
University of ZurichUniversity Hospital, Zürich; Swiss MS Society; Data Management, Clinical Trials...TerminatedAcute Autoimmune Inflammatory Optic NeuritisSwitzerland
-
New York State Psychiatric InstituteSuspended
-
Robert SilbergleitMedical University of South Carolina; National Institute of Neurological Disorders... and other collaboratorsCompletedStatus EpilepticusUnited States
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Research Foundation for Mental Hygiene...Completed
-
University Health Network, TorontoCompletedUpper Limb Surgery | Iliac Crest Bone HarvestCanada
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico